Posted on 19/06/2009 in Pharmaceutical Company Restructures Pfizer expects the acquisition of Wyeth to be completed by the fourth quarter of 2009, it has stated.
The Securities and Exchange Commission declared the company's registration statement on form S-4 ? which lists the company's common stock to be issued in connection with the pending merger - as effective.
On July 20th, Wyeth will hold its annual stockholders meeting where there will be a vote on the acquisition agreement with Pfizer.
Under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, the expiration of the waiting period will govern when the completion of the transaction can take place.
Other jurisdictions include approval of Wyeth stockholders, as well as other usual and customary closing conditions.
Pfizer commented: "Subject to the satisfaction of the foregoing conditions, it is expected that the transaction will close at the end of the third quarter or during the fourth quarter of 2009."
The company yesterday (June 18th) invited the general public and investors to watch a webcast of an announcement of the firm's second quarter 2009 performance results on Jul 22nd.Other news stories from 19/06/2009
Read more in the Zenopa News Archive
How this news is generated
|
